Healthcare Stocks Review: TearLab Corporation, MediciNova, Peregrine Pharmaceuticals, Arena Pharmaceuticals

Lakeway, TX -- (SBWIRE) -- 03/21/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

TearLab Corporation(NASDAQ:TEAR) fell 1.93% and is trading at $6.61. TearLab Corp. is an in-vitro diagnostic company. The Company is commercializing a tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care.

How Should Investors Trade TEAR After The Recent Movement? Find Out Here

MediciNova, Inc.(NASDAQ:MNOV) is trading at $2.96. MediciNova, Inc. is a development-stage biopharmaceutical company focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs with a focus on the United States market. Through strategic alliances, primarily with Japanese pharmaceutical companies, it holds rights to a diversified portfolio of clinical and preclinical product candidates.

Is MNOV Strong Buy After The Recent Strong Gains? Get Free Trend Analysis Here

Peregrine Pharmaceuticals(NASDAQ:PPHM) fell 1.42% and is trading at $1.39. Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer. The Company's pipeline of investigational monoclonal antibodies is based on two technology platforms, including PS-targeting antibodies and DNA/histone-targeting antibodies.

Is PPHM a Buying Opportunity After The Recent Plunge? Don’t Miss Out Our Latest Report Here

Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) is lower 2.15% and is trading at $7.73. Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
How Should Investors Trade ARNA After The Latest Earnings Report? Find Out Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.